The Role of the Incretin Hormones GIP and GLP-1 in the Pathogenesis of Type 2 Diabetes

被引：0
|
作者：
Meier, J. J. [1 ]
机构：
[1] Klinikum Ruhr Univ Bochum, St Josef Hosp, Med Klin 1, D-44791 Bochum, Germany
来源：
DIABETOLOGIE UND STOFFWECHSEL | 2009年 / 4卷 / 05期
关键词：
GASTRIC-INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE-1; DEPENDENT INSULINOTROPIC POLYPEPTIDE; 1ST-DEGREE RELATIVES; ORAL GLUCOSE; RECEPTOR EXPRESSION; 7-36; AMIDE; SECRETION; PLASMA; HYPERGLYCEMIA;
D O I：
10.1055/s-0029-1224610
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The incretin effect, i.e. the postprandial augmentation of insulin secretion by gastrointestinal hormones, mediates similar to 50-70% of the meal-related increments in insulin secretion in healthy individuals. In contrast, the incretin effect is almost completely absent in patients with type 2 diabetes. The impaired incretin effect in type 2 diabetes has been mainly attributed to the reduced insulinotropic activity of GIP, whereas the actions of GLP-1 are largely preserved. Furthermore, a diminished secretion of GLP-1 has been suggested to contribute to the impaired incretin effect in type 2 diabetes, but this finding has not been confirmed in the majority of studies. This article aims to compare the secretion and action of the incretins GIP and GLP-1 between patients with type 2 diabetes and healthy individuals. In addition, the importance of alterations in the entero-insular axis for the pathogenesis of type 2 diabetes will be discussed.
引用
收藏
页码：295 / 300
页数：6
相关论文
共 50 条
  • [21] GIP and GLP-1: Stepsiblings Rather Than Monozygotic Twins Within the Incretin Family
    Nauck, Michael A.
    Meier, Juris J.
    DIABETES, 2019, 68 (05) : 897 - 900
  • [22] From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy
    Holst, Jens Juul
    FRONTIERS IN ENDOCRINOLOGY, 2019, 10
  • [23] The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes
    Frias, Juan Pablo
    Bastyr, Edward J., III
    Vignati, Louis
    Tschoep, Matthias H.
    Schmitt, Christophe
    Owen, Klara
    Christensen, Rune Haubo
    DiMarchi, Richard D.
    CELL METABOLISM, 2017, 26 (02) : 343 - +
  • [24] A Physiologically-Based Quantitative Systems Pharmacology Model of the Incretin Hormones GLP-1 and GIP and the DPP4 Inhibitor Sitagliptin
    Balazki, Pavel
    Schaller, Stephan
    Eissing, Thomas
    Lehr, Thorsten
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2020, 9 (06): : 353 - 362
  • [25] Reduced postprandial GLP-1 responses in women with gestational diabetes mellitus
    Bonde, L.
    Vilsboll, T.
    Nielsen, T.
    Bagger, J. I.
    Svare, J. A.
    Holst, J. J.
    Larsen, S.
    Knop, F. K.
    DIABETES OBESITY & METABOLISM, 2013, 15 (08) : 713 - 720
  • [26] Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP
    Theodorakis, MJ
    Carlson, O
    Michopoulos, S
    Doyle, ME
    Juhaszova, M
    Petraki, K
    Egan, JM
    AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2006, 290 (03): : E550 - E559
  • [27] The Role of GIP in the Regulation of GLP-1 Satiety and Nausea
    Hayes, Matthew R.
    Borner, Tito
    De Jonghe, Bart C.
    DIABETES, 2021, 70 (09) : 1956 - 1961
  • [28] Research Progress on the GIP/GLP-1 Receptor Coagonist Tirzepatide, a Rising Star in Type 2 Diabetes
    Ma, Zijun
    Jin, Kaiqin
    Yue, Mengmeng
    Chen, Xin
    Chen, Jun
    JOURNAL OF DIABETES RESEARCH, 2023, 2023
  • [29] Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
    Gallwitz, Baptist
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [30] Differential incretin effects of GIP and GLP-1 on gastric emptying, appetite, and insulin-glucose homeostasis
    Edholm, T.
    Degerblad, M.
    Gryback, P.
    Hilsted, L.
    Holst, J. J.
    Jacobsson, H.
    Efendic, S.
    Schmidt, P. T.
    Hellstrom, P. M.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2010, 22 (11) : 1191 - +
12345